U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07244406) titled 'Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL' on Nov. 17.
Brief Summary: To evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL.
Study Start Date: Jan. 10
Study Type: INTERVENTIONAL
Condition:
B-ALL
Intervention:
BIOLOGICAL: S1904 CD19 CAR-T
Autologous CD19-targeting CAR T cells
Recruitment Status: RECRUITING
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....